Showing results (281-290 of 292) with videos related to

Sort By:
Pageof 30
Applied Health Economics and Health Policy|November 8, 2019
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of OlaratumabCaridad Pontes, Corinne Zara, Josep Torrent-Farnell, et al.
Frontiers in Pharmacology|October 14, 2016
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive PathwaysMichael Ermisch, Anna Bucsics, Patricia Vella Bonanno, et al.
Plos One|December 29, 2017
Policies for biosimilar uptake in Europe: An overviewEvelien Moorkens, Arnold G Vulto, Isabelle Huys, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 31, 2019
Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTAPatricia Vella Bonanno, Anna Bucsics, Steven Simoens, et al.
Frontiers in Pharmacology|August 13, 2016
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FutureWinnie de Bruijn, Cristina Ibáñez, Pia Frisk, et al.
Frontiers in Pharmacology|September 8, 2017
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential ImplementationPatricia Vella Bonanno, Michael Ermisch, Brian Godman, et al.
Pharmacoeconomics|August 1, 2020
Integrative Review of Managed Entry Agreements: Chances and LimitationsCarolina Zampirolli Dias, Brian Godman, Ludmila Peres Gargano, et al.
BMC Medicine|August 15, 2013
Personalizing health care: feasibility and future implicationsBrian Godman, Alexander E Finlayson, Parneet K Cheema, et al.
Frontiers in Pharmacology|May 30, 2013
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugsRickard E Malmström, Brian B Godman, Eduard Diogene, et al.
Pageof 30